Evercore ISI initiated coverage of Rapt Therapeutics with an Outperform rating and no price target. The company is reporting a high profile Phase 2b in atopic detritus with an oral drug in mid-2024, the analyst tells investors in a research note. The firm believes Rapt has a “real chance” at demonstrating an efficacy significance. Evercore finds the stock’s risk/reward as “very good” at current levels.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on RAPT:
